Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TreeTop: Itulazax in Pediatric Birch Pollen Allergy
NCT04878354Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of SQ SLIT-tablet in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by ALK-Abelló. Primary endpoint: Average Total Combined Score During the Birch Pollen Season. Started Apr 2021; status: completed.
02
Drugs
SQ SLIT-tablet
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT04878354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878354.